Cryosite (ASX:CTE) 5-Year EBITDA Growth Rate : 62.10% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Cryosite 5-Year EBITDA Growth Rate?

Cryosite's EBITDA per Share for the six months ended in Dec. 2023 was A$0.03.

During the past 12 months, Cryosite's average EBITDA Per Share Growth Rate was 15.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 3.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 62.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cryosite was 114.00% per year. The lowest was -43.10% per year. And the median was 3.00% per year.

Competitive Comparison of Cryosite's 5-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Cryosite's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryosite's 5-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cryosite's 5-Year EBITDA Growth Rate falls into.

Cryosite 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Cryosite (ASX:CTE) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Cryosite 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Cryosite's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryosite (ASX:CTE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cryosite Ltd (ASX:CTE) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142

Website

https://www.cryosite.com

Cryosite Ltd is engaged in the provision of supply chain logistics, management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services.

Cryosite (ASX:CTE) Headlines

No Headlines